Evaluation of Safety and Efficacy of Dehydrated Human Amnion-Intermediate-Chorion Membrane (dHAICM) Allograft in Treatment of Partial Thickness Thermal Burns

Inclusion Criteria: * 18 years of age or older * One or more thermal burns classified as either superficial partial thickness or deep partial thickness. * Total Body Surface Area (TBSA) involvement between 5% and 15%. * Total burn index wound area is greater than 25 cm 2 and less than 0.25 m 2 (2500 cm 2 ) * 1 If 2 or more burns are present, each must have an area greater than 15 cm 2 * The participant must be willing and able to participate in the informed consent process. Exclusion Criteria: * Full thickness burns. * Burns present for \>72 hours prior to study evaluation * Burns requiring immediate autografting. * Superficial burns (1 st -degree) or burns not meeting criteria to be included in TBSA calculations. * Chemical or electrical burns. * Burns secondary to blast injury. * Burns causing vascular or respiratory compromise and burns requiring escharotomy * Any severe systemic comorbidities which could impair healing (e.g. active sepsis or major organ failure). * Known coagulopathy, platelet disorder, INR \> 1.6, PTT \> 38s, or platelets \< 50,000 per mm 3 * Uncontrolled diabetes. * Known life expectancy of \< 6 months. * Evidence of active infection in burn. * Target area for treatment includes the head, neck, palms of hands, soles of the feet, or genitals. * Viral infection which could impair healing or immune function (e.g. HIV, HBV, HCV) * Participants of childbearing potential who are pregnant, considering becoming pregnant within the next 6 months, and/or are unwilling to utilize an appropriate form of contraception. * Currently requiring dialysis or planning to start within 6 months. * Medical or psychological condition that, in the opinion of the investigator, may interfere with study assessments. * Treated with hyperbaric oxygen therapy or a skin substitute within the 30 days prior to screening visit. * Sensitivity to ofloxacin, vancomycin, or amphotericin antibiotics. * Participation in a clinical trial involving treatment with an investigational product within the previous 30 days.